AU2002359431A1 - Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases - Google Patents

Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases

Info

Publication number
AU2002359431A1
AU2002359431A1 AU2002359431A AU2002359431A AU2002359431A1 AU 2002359431 A1 AU2002359431 A1 AU 2002359431A1 AU 2002359431 A AU2002359431 A AU 2002359431A AU 2002359431 A AU2002359431 A AU 2002359431A AU 2002359431 A1 AU2002359431 A1 AU 2002359431A1
Authority
AU
Australia
Prior art keywords
interleukin
susceptibility
inflammatory
infectious diseases
affecting transcription
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002359431A
Other versions
AU2002359431A8 (en
Inventor
Nazneen Aziz
Gordon W. Duff
Chung Ming Hsieh
D. Wyllie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Interleukin Genetics Inc
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Publication of AU2002359431A1 publication Critical patent/AU2002359431A1/en
Publication of AU2002359431A8 publication Critical patent/AU2002359431A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/204—Modifications characterised by specific length of the oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002359431A 2001-11-19 2002-11-19 Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases Abandoned AU2002359431A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33168101P 2001-11-19 2001-11-19
US60/331,681 2001-11-19
US38602002P 2002-06-05 2002-06-05
US60/386,020 2002-06-05
PCT/US2002/037222 WO2003044176A2 (en) 2001-11-19 2002-11-19 Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases

Publications (2)

Publication Number Publication Date
AU2002359431A1 true AU2002359431A1 (en) 2003-06-10
AU2002359431A8 AU2002359431A8 (en) 2003-06-10

Family

ID=26987865

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002359431A Abandoned AU2002359431A1 (en) 2001-11-19 2002-11-19 Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases

Country Status (8)

Country Link
US (2) US20030235890A1 (en)
EP (1) EP1463745A4 (en)
JP (2) JP4492849B2 (en)
KR (2) KR101019131B1 (en)
CN (2) CN101955943A (en)
AU (1) AU2002359431A1 (en)
CA (1) CA2467717A1 (en)
WO (1) WO2003044176A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
CA2378221A1 (en) * 1999-06-30 2001-01-04 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
US20070264645A1 (en) * 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
ATE389034T1 (en) * 2002-09-30 2008-03-15 Novartis Pharma Gmbh METHOD FOR PREDICTING INCREMENTS OF CHOLESTEROL DURING IMMUNOSUPPRESIVE THERAPY
US20050175721A1 (en) * 2004-02-06 2005-08-11 Brovelli Ernesto A. Method of augmenting the immune-modulatory activity of standardized Echinacea preparations
EP1720893B1 (en) * 2004-02-26 2014-08-13 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
WO2005108619A2 (en) * 2004-05-03 2005-11-17 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype
WO2006022277A1 (en) * 2004-08-24 2006-03-02 Fujifilm Corporation Method for calculating dissociation constant in surface plasmon resonance analysis
JP2006262826A (en) * 2005-03-25 2006-10-05 Institute Of Physical & Chemical Research Method for examining inflammatory disease on basis of polymorphism of interleukin-1 receptor 2 gene
US8105775B2 (en) * 2005-10-25 2012-01-31 Interleukin Genetics, Inc. IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
JP4870976B2 (en) * 2005-11-10 2012-02-08 株式会社Ｄｎａチップ研究所 Test method for autoimmune disease using whole blood
ES2431671T3 (en) * 2006-11-15 2013-11-27 Interleukin Genetics, Inc. The IL-1 gene complex and insulin resistance: associated polymorphisms, haplotypes and methods to use them
US20090170105A1 (en) * 2007-11-08 2009-07-02 Interleukin Genetics, Inc. Diagnostics for Aging-Related Dermatologic Disorders
WO2017123696A1 (en) 2016-01-12 2017-07-20 Interleukin Genetics, Inc. Methods for predicting response to treatment
KR102543907B1 (en) * 2016-06-17 2023-06-15 서울대학교산학협력단 A genetic marker for evaluating risk of periodontitis
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
JP7097855B2 (en) * 2019-04-24 2022-07-08 ジェネシスヘルスケア株式会社 How to determine the risk of periodontal disease
EP3980561A1 (en) 2019-06-06 2022-04-13 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19
WO2022040090A1 (en) * 2020-08-17 2022-02-24 The Regents Of The University Of California Application of microbial glycosidase as an anti-viral therapeutic, prognostic, and diagnostic

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) * 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4833080A (en) * 1985-12-12 1989-05-23 President And Fellows Of Harvard College Regulation of eucaryotic gene expression
US4998617A (en) * 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US4968607A (en) * 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5593826A (en) * 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5686246A (en) * 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
GB9621129D0 (en) * 1996-10-10 1996-11-27 Duff Gordon W Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6210877B1 (en) 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US6524795B1 (en) 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
GB9723553D0 (en) * 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US6437216B1 (en) * 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
CA2378221A1 (en) 1999-06-30 2001-01-04 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype
WO2001021594A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
US6617329B2 (en) * 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
US6656946B2 (en) * 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
CA2450809A1 (en) 2001-06-15 2002-12-27 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US8071304B2 (en) * 2003-04-05 2011-12-06 The Johns Hopkins University Methods for detecting a polymorphism in the NFKB1 gene promoter

Also Published As

Publication number Publication date
KR101019131B1 (en) 2011-03-07
CN1753903A (en) 2006-03-29
CA2467717A1 (en) 2003-05-30
KR101059898B1 (en) 2011-08-29
US20100279280A1 (en) 2010-11-04
US20030235890A1 (en) 2003-12-25
KR20100095652A (en) 2010-08-31
JP4492849B2 (en) 2010-06-30
KR20040066832A (en) 2004-07-27
JP2010029220A (en) 2010-02-12
EP1463745A2 (en) 2004-10-06
EP1463745A4 (en) 2007-11-07
AU2002359431A8 (en) 2003-06-10
JP2005509432A (en) 2005-04-14
WO2003044176A8 (en) 2003-08-21
WO2003044176A9 (en) 2003-10-16
CN1753903B (en) 2010-05-12
WO2003044176A2 (en) 2003-05-30
WO2003044176A3 (en) 2004-07-29
CN101955943A (en) 2011-01-26

Similar Documents

Publication Publication Date Title
AU2002359431A1 (en) Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
EP1578691B8 (en) Separation and purification of fullerenes
AU2002361563A1 (en) Anti-tombstoning structures and methods of manufacture
AU2003286657A1 (en) Filters and methods of making and using the same
AU2003284197A1 (en) Microstructures and methods of fabrication thereof
AU2002327872A1 (en) Improvement to methods for the continuous production of acetic acid and/or methyl acetate
AU2003293644A1 (en) Moldings and preparation and uses thereof
AU2002335085A1 (en) Angiopoietins and methods of use thereof
AU2002247269A1 (en) Genes and polymorphisms associated with cardiovascular disease and their use
AU2002341542A1 (en) Transcription factors of cereals
PL363080A1 (en) Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
AU2002241911A1 (en) Methods to treat autoimmune and inflammatory conditions
AU2002309180A1 (en) Composition and kit for the treatment of inflammatory bowel diseases
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
AU2002252387A1 (en) Novel anti-inflammatory compositions and methods of use
EP1572899A3 (en) The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
AU2003228651A1 (en) Telescopic collimator and method of manufacture
AU2003287802A1 (en) Palpometer and methods of use thereof
AU2003290249A1 (en) Purification of nanotubes
AU2002366809A1 (en) Syn3 compositions and methods
AU2003242736A1 (en) Titaniun-vanadium-tin comprising catalyst and process for the preparation of phthalic anhydride
AU2003215246A1 (en) Methods of reducing rhinovirus contagion and related compositions
AU2002242086A1 (en) Chemomagnetic retrieval of cmv and cmv infected cells
AU2003225677A1 (en) Drag reducing compositions and methods of manufacture and use
AU2002357039A1 (en) Polymorphism and haplotype scoring by differential amplification of polymorphisms

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase